Seeking Alpha

pault123

pault123
Send Message
View as an RSS Feed
View pault123's Comments BY TICKER:
Latest  |  Highest rated
  • GCVRZ Forum [View instapost]
    Maybe some day Lemtrada will get approved.
    -------------
    FDA approves Biogen Idec’s multiple sclerosis drug
    http://bit.ly/1m6Jp6s
    Aug 16 09:24 PM | 1 Like Like |Link to Comment
  • GCVRZ Forum [View instapost]
    Genzyme MS drug to become available in the UK
    http://bit.ly/TVMvmz
    May 28 10:58 PM | 3 Likes Like |Link to Comment
  • GPT Forum [View instapost]
    Gramercy Property Trust Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
    http://bit.ly/OopAgj?
    Mar 13 11:18 AM | Likes Like |Link to Comment
  • CommonWealth REIT Issues Statement Regarding Sam Zell [View article]
    The Portnoys are grasping at straws.
    Mar 3 04:18 PM | Likes Like |Link to Comment
  • Jos. A. Bank rejects Men's Wearhouse's $63.50 offer [View news story]
    Mergers & Acquisitions | Deal Professor February 28, 2014
    A Scorecard on Jos. A. Bank’s Latest Moves
    By STEVEN M. DAVIDOFF

    http://nyti.ms/1hx8RBE
    Feb 28 07:49 PM | Likes Like |Link to Comment
  • Special Situations Update: NuPathe Correction [View article]
    Liegh,
    The NuPathe document states that only in “rare and extraordinary cases” is the value of property so uncertain as to warrant open transaction treatment. However, NuPathe and the Paying Agent have each agreed in the CPRs that it generally will not act in a manner inconsistent with the characterization of the CPRs as having been issued in an “open transaction.”
    So my thinking now is to take a capital loss based on purchase price minus $3.65. But when the Contingent Payments are made, I would have a $0 cost basis.
    PaulT
    Feb 26 08:27 PM | Likes Like |Link to Comment
  • Special Situations Update: NuPathe Correction [View article]
    Liegh,
    The tax treatment of Contingent Value Rights/ Contingent Payment Rights is unclear.

    It’s a bit too long to copy and paste here, but NuPathe spent about 2 pages discussing this topic in one of their filings: FORM SC TO-T NUPATHE INC. – PATH Filed: January 23, 2014 (period: ). I will refer you to that document’s section 5 “Certain Material United States Federal Income Tax Consequences of the Offer and the Merger” and the discussion of whether this is characterized as an open or closed transaction. To summarize, it depends on whether the value of the CPRs can or cannot be “reasonably ascertained” after the merger as to how the transaction is characterized and therefore the tax treatment.

    PaulT
    Feb 24 11:02 PM | Likes Like |Link to Comment
  • National Interstate: Squeeze-Out Tender Materially Undervalues The Company [View article]
    An update:

    National Interstate: Controller Had Thumb On Scale, Asserts Independent Director - We Are Shocked, Shocked!
    http://seekingalpha.co...?
    Feb 24 02:25 PM | Likes Like |Link to Comment
  • Seeking Truth From Facts – Tuesday, December 03, 2013 [View instapost]
    The Final Battle for a REIT May Be Drawing Near
    http://nyti.ms/1p30x0v?
    Feb 21 04:03 PM | Likes Like |Link to Comment
  • Special Situations Update: NuPathe Correction [View article]
    Teva Completes Tender Offer for NuPathe Inc. Shares
    http://yhoo.it/MIIspQ
    Feb 21 12:30 PM | Likes Like |Link to Comment
  • Sanofi's Viehbacher Says Lemtrada Can Still Be A Big Success [View instapost]
    Teva rises after FDA OKs higher-dosage Copaxone. Teva's (TEVA) shares were +2.9% premarket after the FDA approved a 40 mg dose of the company's multiple sclerosis drug Copaxone that would be administered three times a week. Teva plans to convert 57% of patients to the new regimen by the year-end from the daily dose of 20 mg. The longer-lasting formulation should help Teva cope with generic competition when Copaxone's patent protection expires in May. The higher-dosage version is protected until 2030. (PR)
    Jan 29 09:04 AM | Likes Like |Link to Comment
  • GCVRZ: Betting On The Sales Of Lemtrada In A Moving MS Drug Market [View article]
    nkagalwala,
    These links may provide a start to your MS drug sales question:

    http://bit.ly/1bgRks4
    http://bit.ly/1bgRlfI
    http://bit.ly/1bgRlfM

    PaulT
    Jan 21 09:16 PM | Likes Like |Link to Comment
  • GCVRZ: Betting On The Sales Of Lemtrada In A Moving MS Drug Market [View article]
    462812,
    My guess is that this is where the official sales tally will be kept.
    http://bit.ly/1jMVGjW

    PaulT
    Jan 20 10:25 AM | 1 Like Like |Link to Comment
  • GCVRZ Forum Archive  [View instapost]
    This is from one of the original CVR documents.
    ------------
    The Approval Milestone Payment will be paid twenty business days after the achievement of such milestone.

    With respect to Product Sales Milestones, fifty days after the end of each calendar quarter, Parent is required to provide a statement of net sales of Lemtrada to the trustee that includes (i) a calculation of net sales of Lemtrada with respect to the last completed four-quarter period, (ii) notice of whether any Product Sales Milestone has been achieved and (iii) for each calendar quarter ending on or prior to December 31, 2011, the production totals for Cerezyme and Fabrazyme since January 1, 2011, reported on a quarterly basis and expressed, in the case of Cerezyme, in units of 400 unit-vial equivalents and, in the case of Fabrazyme, in units of 35-milligram unit vial equivalents, as well as notice of whether the Production Milestone has been achieved as of the end of such calendar quarter. Parent must pay any Product Sales Milestone Payment twenty business days following notice of the achievement of such milestone in the product sales statement described above.

    All milestone payments shall be made to holders of record of the CVRs as of the close of business in New York City, three business days prior to the relevant payment date. Amounts payable by Parent in respect of the CVRs will be considered paid on the date due if on such date the trustee or paying agent holds money sufficient to pay all such amounts then due in accordance with the CVR Agreement. The trustee and paying agent will comply with all U.S. federal withholding requirements with respect to payments to holders of CVRs that Parent, the trustee or the paying agent reasonably believes are applicable under the Code and the treasury regulations thereunder. The consent of the CVR holder is not required for any such withholding.
    Dec 26 07:58 PM | Likes Like |Link to Comment
  • GCVRZ Forum Archive  [View instapost]
    There's not much information there now, but my guess is that this is where the official sales tally will be kept.

    http://bit.ly/1jMVGjW
    Dec 26 06:00 PM | 1 Like Like |Link to Comment
COMMENTS STATS
52 Comments
16 Likes